Search results for " Metastasis."

showing 10 items of 617 documents

Lymph node metastases displaying lower Ki-67 immunostaining activity than the primary breast cancer

2007

The aim of the study was to verify by Ki-67 immunostaining if any difference exists in the cell proliferating fraction between primary breast tumors (PTs) and matching positive axillary lymph nodes (ALNs). PATIENTS AND METHODS: Immunohistochemistry with the monoclonal antibody against Ki-67 was performed in 160 node-positive breast carcinomas and in their respective lymph node metastases. RESULTS: An increase of Ki-67 immunoreactive cells in ALN compared with that of PTs was observed in 84% of cases (ALN: mean 17%, PTs: mean 8%; p < 0.001), whereas 16% of the cases showed Ki-67 value two to six times lower in the ALNs than in the corresponding PTs (ALN: mean 3.2%, PTs mean 12.5%; p < 0.005)…

Metastases; Immunohistochemistry; Breast cancerBreast cancerKi-67 AntigenLymphatic MetastasisMetastaseHumansBreast NeoplasmsFemaleSettore MED/08 - Anatomia PatologicaImmunohistochemistry
researchProduct

Itraconazole inhibits nuclear delivery of extracellular vesicle cargo by disrupting the entry of late endosomes into the nucleoplasmic reticulum

2021

ABSTRACT Extracellular vesicles (EVs) are mediators of intercellular communication under both healthy and pathological conditions, including the induction of pro‐metastatic traits, but it is not yet known how and where functional cargoes of EVs are delivered to their targets in host cell compartments. We have described that after endocytosis, EVs reach Rab7+ late endosomes and a fraction of these enter the nucleoplasmic reticulum and transport EV biomaterials to the host cell nucleoplasm. Their entry therein and docking to outer nuclear membrane occur through a tripartite complex formed by the proteins VAP‐A, ORP3 and Rab7 (VOR complex). Here, we report that the antifungal compound itracona…

Models MolecularHistologyAntifungal AgentsEndosomeNuclear EnvelopeNucleoplasmic reticulumActive Transport Cell NucleusVesicular Transport ProteinsHost cell nucleoplasmEndosomesEndocytosisFatty Acid-Binding ProteinsExosomeCell LineExtracellular VesiclesCell MovementSettore BIO/13 - Biologia ApplicataHumanscancerexosomemetastasisendosomeResearch ArticlesCholestenonesmicro‐vesicleQH573-671Chemistryrab7 GTP-Binding ProteinsCell BiologyExtracellular vesicleSaponinsEndocytosisCell biologyKetoconazoleCancer cellintercellular communicationnucleoplasmic reticulumcancer endosome exosome intercellular communication metastasis micro-vesicle nucleoplasmicreticulumItraconazoleCytologyIntracellularResearch ArticleJournal of Extracellular Vesicles
researchProduct

Investigating the possible impact of peritoneal tumor exposure amongst women with early stage cervical cancer treated with minimally invasive approac…

2021

Abstract Introduction Recent findings show a detrimental impact of the minimally invasive approach on patients with early stage cervical cancer (ECC). Reasons beyond these results are unclear. The aim of the present article is to investigate the possible role of peritoneal contamination during intracorporeal colpotomy. Methods patients with early stage cervical cancer were divided into 2 groups: no intraperitoneal exposure (N-IPE) intraperitoneal exposure (IPE) during minimally invasive surgery. Patients of the 2 groups were propensity-matched according to the major risk factors. Results 226 cases of the IPE group had a significant worst prognosis than the 142 cases of the N-IPE group (4.5-…

Multivariate analysisPeritoneal tumorUterine Cervical NeoplasmsColpotomy0302 clinical medicineRisk Factors80 and overRadical hysterectomyStage (cooking)Prospective cohort studyLaparoscopyPeritoneal CavityCervical cancerAged 80 and over030219 obstetrics & reproductive medicinemedicine.diagnostic_testHazard ratioCervical cancer; Laparoscopy; Minimally invasive; Peritoneal contamination; Radical hysterectomyGeneral MedicineMiddle AgedPrognosisSurvival RateOncologyItaly030220 oncology & carcinogenesisPeritoneal contaminationLymphatic MetastasisFemaleAdultmedicine.medical_specialty03 medical and health sciencesInternal medicinemedicineHumansMinimally Invasive Surgical ProceduresMinimally invasivePropensity ScoreAgedNeoplasm StagingRetrospective Studiesbusiness.industrymedicine.diseaseConfidence intervalSettore MED/40 - GINECOLOGIA E OSTETRICIACervical cancerLymph Node ExcisionSurgeryLaparoscopyNeoplasm GradingbusinessEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
researchProduct

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

2014

International audience; The immune system is routinely confronted with cell death resulting from the physiological turnover of renewable tissues, as well as from pathological insults of several types. We hypothesize the existence of a mechanism that allows the immune system to discriminate between physiological and pathological instances of cell death, but the factors that determine whether cellular demise is perceived as a neutral, tolerogenic or immunogenic event remain unclear 1. Infectious insults are accompanied by so-called microbe-associated molecular patterns (MAMPs), i.e., viral or bacterial products that activate immune cells through a panel of pattern-recognition receptors (PRRs)…

Myxovirus Resistance ProteinsMessengerReceptor Interferon alpha-betaInbred C57BLchemotherapyInterferon alpha-betaMiceInterferonReceptorsAnthracyclinesNeoplasm MetastasisRIG-IPattern recognition receptorAdaptor ProteinsGeneral MedicineNeoadjuvant Therapy3. Good healthGene Expression Regulation NeoplasticTreatment OutcomeReceptors Pattern RecognitionInterferon Type I[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemaleImmunocompetencemedicine.drugReceptorSignal TransductionBreast Neoplasms[SDV.CAN]Life Sciences [q-bio]/CancerBiologyPattern RecognitionSettore BIO/09General Biochemistry Genetics and Molecular BiologyParacrine signallingImmune systemmedicineCXCL10AnimalsHumanscancerRNA MessengerAutocrine signallingNeoplastic[SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/ImmunotherapyToll-Like Receptor 3Mice Inbred C57BLVesicular TransportChemokine CXCL10Adaptor Proteins Vesicular TransportGene Expression RegulationDoxorubicinImmunologyTLR3RNAAdaptor Proteins Vesicular Transport; Animals; Anthracyclines; Breast Neoplasms; Chemokine CXCL10; Doxorubicin; Female; Gene Expression Regulation Neoplastic; Humans; Immunocompetence; Interferon Type I; Mice Inbred C57BL; Myxovirus Resistance Proteins; Neoadjuvant Therapy; Neoplasm Metastasis; RNA; RNA Messenger; Receptor Interferon alpha-beta; Receptors Pattern Recognition; Toll-Like Receptor 3; Treatment Outcome; Signal Transduction
researchProduct

Predictive Score of Nodal Involvement in Endometrial Cancer Patients: A Large, Multicenter Series

2022

N.A.

N.A.OncologyLymphatic MetastasisHumansFemaleSurgeryEndometrial NeoplasmsNeoplasm StagingRetrospective StudiesAnnals of Surgical Oncology
researchProduct

Malignant and benign sinonasal paragangliomas

2013

Objectives/Hypothesis To report on the clinical course and management of sinonasal paragangliomas (PGLs). Study Design and Methods Retrospective chart review of six patients with PGLs of the nasal cavity and paranasal sinuses. Results Three patients had tumors with malignant clinical behavior with cerebral metastases or infiltration of brain and local recurrence, despite surgery and/or radiotherapy, while three patients demonstrated a benign course. Conclusion Sinonasal paragangliomas are frequently malignant. If malignant, they are very aggressive, with rapid local spread as well as high metastatic potential despite surgical resection; and they have a poor prognosis. Malignancy cannot be d…

Nasal cavityPoor prognosismedicine.medical_specialtybusiness.industrymedicine.medical_treatmentIntracranial metastasisClinical courseMalignancymedicine.diseaseSurgeryMetastasisRadiation therapymedicine.anatomical_structureParanasal sinusesOtorhinolaryngologyMedicinebusinessThe Laryngoscope
researchProduct

Huge isolated port-site recurrence after laparoscopic partial nephrectomy: a case report.

2009

A 66-yr-old man with pain and swelling in the right flank was referred to our clinic for diagnosis. In 2005, the patient underwent a laparoscopic partial nephrectomy for renal cancer of the lower pole of the right kidney. A computed tomography scan revealed a 20-cm tumor in the right abdominal wall, resulting in a suspected diagnosis of port-site metastasis from the first laparoscopic operation. The patient underwent open surgery, which confirmed the diagnosis. After the operation, the patient recovered rapidly.

NephrologyMalemedicine.medical_specialtyUrologymedicine.medical_treatmentNephrectomySettore MED/24 - UrologiaMetastasisLaparoscopynephrectomy recurrenceAbdominal wallNeoplasm SeedingInternal medicinePort-site metastasismedicineHumansLaparoscopyKidney cancer; Laparoscopy; Port-site metastasisCarcinoma Renal CellAgedmedicine.diagnostic_testbusiness.industryAbdominal WallKidney cancermedicine.diseaseNephrectomyKidney NeoplasmsSurgeryEndoscopymedicine.anatomical_structureLaparoscopybusinessKidney cancerKidney diseaseEuropean urology
researchProduct

Open Radical Nephrectomy: 35 Years of Experience at the “Luciano Giuliani” Urological Department of the University of Genoa

2006

Objective: Radical nephrectomy remains the gold standard for surgically resectable kidney neoplasms &gt; 4 cm and, in selected cases, also in presence of metastatic disease. We reviewed the records of the patients having surgery at the University of Genoa in the last 35 yr. Methods: We have retrospectively assessed all the radical nephrectomies performed between 1970 and 2005. Among tumours of the kidney subjected to surgical treatment during this period, we found 1105 cases of histologically proven renal cell carcinoma (RCC), 965 of which had records available for the study. The number of cases per year, symptoms at diagnosis, surgical strategy, staging of the tumour, and survival were rev…

Nephrologycancer incidencemedicine.medical_treatmentkidney carcinomamorbiditysepsisRenal cell carcinomacancer diagnosiscancer mortalitynephrectomypostoperative complicationMyocardial infarctioncancer survivaldisease free survivalcancer diagnosiadrenalectomy; article; cancer diagnosis; cancer incidence; cancer mortality; cancer size; cancer staging; cancer surgery; cancer survival; disease free survival; heart infarction; human; kidney carcinoma; lung embolism; lymphadenectomy; metastasis; morbidity; nephrectomy; partial nephrectomy; postoperative complication; priority journal; sepsis; spleen injury; splenectomy; surgical technique; thrombectomyRadical nephrectomyIncidence (epidemiology)articleadrenalectomyRenal cell carcinomaNephrectomypriority journalthrombectomysepsicancer surgerylung embolismmedicine.medical_specialtypartial nephrectomyUrologyheart infarctionsurgical techniquesplenectomyInternal medicinemedicineCarcinomametastasishumanbusiness.industrycancer stagingmedicine.diseaseSurgeryspleen injurycancer sizelymphadenectomySurgerymetastasibusinessKidney cancerKidney diseaseEuropean Urology Supplements
researchProduct

Extrahepatic spread of hepatocellular carcinoma

2012

Hepatocellular carcinoma (HCC) is a major health problem. The treatment of HCC depends on the tumour stage and on the severity of underlying cirrhosis, however, a majority of HCC patients have advanced disease at presentation. In recent years extra-hepatic spread (ES) of HCC seems to have been observed more frequently than in the past even if few data exist in literature on prevalence, clinical presentation and prognosis of patients with HCC ES. Aim of this brief review is underline the main concerns, pitfalls and warnings in practicing with these patients. ES of HCC are not rare, and the probability of finding ES is higher in patients with advanced intra-hepatic HCC. The more frequent ES s…

NiacinamideSettore MED/12 - GastroenterologiaCarcinoma HepatocellularPhenylurea CompoundsLiver NeoplasmsCarcinomaCarcinoma; Hepatocellular; Neoplasm metastasis; sorafenibAntineoplastic AgentsHepatocellularPrognosisSettore MED/28 - Malattie OdontostomatologicheAnimalsHumansNeoplasm InvasivenesssorafenibMolecular Targeted TherapyProtein Kinase InhibitorsNeoplasm metastasi
researchProduct

The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Pro…

2017

Abstract Background The androgen receptor splice variant 7 (AR-V7) is associated with resistance to hormonal therapy in castration-resistant prostate cancer (CRPC). Due to limitations of the methods available for AR-V7 analysis, the identification of a reliable detection method may facilitate the use of this biomarker in clinical practice. Objective To confirm AR-V7 as a predictor of resistance to hormonal therapy and develop a new approach to assess AR-V7 by highly sensitive digital droplet polymerase chain reaction (ddPCR) in plasma-derived exosomal RNA. Design, setting, and participants Plasma samples were collected from 36 CRPC patients before they began second-line hormonal treatment. …

Oncology0301 basic medicineMaleResistanceExosomeschemistry.chemical_compoundProstate cancer0302 clinical medicineProtein IsoformsNeoplasm MetastasisReceptorAged 80 and overProstate cancerMiddle AgedProstatic Neoplasms Castration-ResistantReceptors Androgen030220 oncology & carcinogenesisBenzamidesAdenocarcinomaBiomarker (medicine)Hormonal therapyAR-V7; Digital droplet PCR; Exosomes; Hormonal therapy; Pharmacogenetics; Prostate cancer; Resistance; UrologyAndrostenesHormonal therapymedicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.drug_classUrologyCastration resistantAdenocarcinomaDisease-Free Survival03 medical and health sciencesSDG 3 - Good Health and Well-beingInternal medicineNitrilesPhenylthiohydantoinmedicineEnzalutamideHumansAgedDigital droplet PCRPlasma derivedbusiness.industryRNAAndrogen Receptor Splice Variant 7medicine.diseaseAndrogenEndocrinology030104 developmental biologychemistryPharmacogeneticsDrug Resistance NeoplasmCancer cellCancer researchRNAAR-V7businessPharmacogenetics
researchProduct